Home/Pipeline/CIB-201

CIB-201

Solid Tumors

PreclinicalActive

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Active

Company

Cellinfinity Bio

About Cellinfinity Bio

Cellinfinity Bio is developing next-generation, 'Supercharged In Vivo Cell Therapies' designed to reprogram a patient's own immune cells inside the body, bypassing the costly and complex ex vivo manufacturing of traditional autologous CAR-T. The company's platform applies directed evolution across four key areas—scFv discovery, vector engineering, CAR design, and genomic enhancements—to create therapies that can overcome the immunosuppressive barriers of solid tumors. With a preclinical pipeline targeting solid tumors, Cellinfinity aims to simplify cell therapy delivery and expand its efficacy beyond hematological cancers into areas of high unmet need.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed